<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nature Medicine</title>
<link>http://feeds.nature.com/nm/rss/current</link>

<item>
<title>Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes</title>
<link>https://www.nature.com/articles/s41591-024-03372-1</link>
<guid>https://www.nature.com/articles/s41591-024-03372-1</guid>
<content:encoded><![CDATA[
<div> <p>Nature Medicine, Published online: 28 October 2024; <a href="https://www.nature.com/articles/s41591-024-03372-1">doi:10.1038/s41591-024-03372-1</a></p>Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes <div>
<p>Nature Medicine, Published online: 28 October 2024; <a href="https://www.nature.com/articles/s41591-024-03372-1">doi:10.1038/s41591-024-03372-1</a></p>Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
]]></content:encoded>

<pubDate>2024-10-28</pubDate>
</item>
<item>
<title>Using AVATAR therapy to conquer auditory hallucinations</title>
<link>https://www.nature.com/articles/s41591-024-03312-z</link>
<guid>https://www.nature.com/articles/s41591-024-03312-z</guid>
<content:encoded><![CDATA[
<div> <p>Nature Medicine, Published online: 28 October 2024; <a href="https://www.nature.com/articles/s41591-024-03312-z">doi:10.1038/s41591-024-03312-z</a></p>AVATAR therapy, in which patient and therapist interact with a digital embodiment of patients’ auditory hallucinations, effectively reduces distress and symptom frequency, which could be a game-changer for patients. <div>
<p>Nature Medicine, Published online: 28 October 2024; <a href="https://www.nature.com/articles/s41591-024-03312-z">doi:10.1038/s41591-024-03312-z</a></p>AVATAR therapy, in which patient and therapist interact with a digital embodiment of patients’ auditory hallucinations, effectively reduces distress and symptom frequency, which could be a game-changer for patients.
]]></content:encoded>

<pubDate>2024-10-28</pubDate>
</item>
<item>
<title>Unprecedented spread and genetic evolution of the Oropouche virus</title>
<link>https://www.nature.com/articles/s41591-024-03336-5</link>
<guid>https://www.nature.com/articles/s41591-024-03336-5</guid>
<content:encoded><![CDATA[
<div> <p>Nature Medicine, Published online: 28 October 2024; <a href="https://www.nature.com/articles/s41591-024-03336-5">doi:10.1038/s41591-024-03336-5</a></p>The current Oropouche fever outbreak has been traced to a novel reassortant virus that emerged about a decade ago, which highlights the importance of One Health surveillance in preventing, predicting, detecting and responding to emerging threats. <div>
<p>Nature Medicine, Published online: 28 October 2024; <a href="https://www.nature.com/articles/s41591-024-03336-5">doi:10.1038/s41591-024-03336-5</a></p>The current Oropouche fever outbreak has been traced to a novel reassortant virus that emerged about a decade ago, which highlights the importance of One Health surveillance in preventing, predicting, detecting and responding to emerging threats.
]]></content:encoded>

<pubDate>2024-10-28</pubDate>
</item>
<item>
<title>Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial</title>
<link>https://www.nature.com/articles/s41591-024-03252-8</link>
<guid>https://www.nature.com/articles/s41591-024-03252-8</guid>
<content:encoded><![CDATA[
<div> <p>Nature Medicine, Published online: 28 October 2024; <a href="https://www.nature.com/articles/s41591-024-03252-8">doi:10.1038/s41591-024-03252-8</a></p>A randomized controlled trial involving people with psychosis who hear distressing voices reported that two different forms of AVATAR therapy, an intervention where voice-hearers engage with a digital avatar representing this distressing voice, reported further improvements in voice-related distress at 16 weeks but not at 28 weeks on top of standard of care. <div>
<p>Nature Medicine, Published online: 28 October 2024; <a href="https://www.nature.com/articles/s41591-024-03252-8">doi:10.1038/s41591-024-03252-8</a></p>A randomized controlled trial involving people with psychosis who hear distressing voices reported that two different forms of AVATAR therapy, an intervention where voice-hearers engage with a digital avatar representing this distressing voice, reported further improvements in voice-related distress at 16 weeks but not at 28 weeks on top of standard of care.
]]></content:encoded>

<pubDate>2024-10-28</pubDate>
</item>
<item>
<title>How health technology can ease the terrible toll of war</title>
<link>https://www.nature.com/articles/s41591-024-03335-6</link>
<guid>https://www.nature.com/articles/s41591-024-03335-6</guid>
<content:encoded><![CDATA[
<div> <p>Nature Medicine, Published online: 25 October 2024; <a href="https://www.nature.com/articles/s41591-024-03335-6">doi:10.1038/s41591-024-03335-6</a></p>Trauma and infections increase during war, while routine cancer care is disrupted, but telemedicine, AI chatbots and electronic health records can help. <div>
<p>Nature Medicine, Published online: 25 October 2024; <a href="https://www.nature.com/articles/s41591-024-03335-6">doi:10.1038/s41591-024-03335-6</a></p>Trauma and infections increase during war, while routine cancer care is disrupted, but telemedicine, AI chatbots and electronic health records can help.
]]></content:encoded>

<pubDate>2024-10-25</pubDate>
</item>
<item>
<title>Political polarization and health</title>
<link>https://www.nature.com/articles/s41591-024-03307-w</link>
<guid>https://www.nature.com/articles/s41591-024-03307-w</guid>
<content:encoded><![CDATA[
<div> <p>Nature Medicine, Published online: 25 October 2024; <a href="https://www.nature.com/articles/s41591-024-03307-w">doi:10.1038/s41591-024-03307-w</a></p>Political polarization is an understudied determinant of health. This Review describes the types of political polarization and how they impact the health of populations and individuals, including potential mitigation strategies and research priorities. <div>
<p>Nature Medicine, Published online: 25 October 2024; <a href="https://www.nature.com/articles/s41591-024-03307-w">doi:10.1038/s41591-024-03307-w</a></p>Political polarization is an understudied determinant of health. This Review describes the types of political polarization and how they impact the health of populations and individuals, including potential mitigation strategies and research priorities.
]]></content:encoded>

<pubDate>2024-10-25</pubDate>
</item>
<item>
<title>Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial</title>
<link>https://www.nature.com/articles/s41591-024-03327-6</link>
<guid>https://www.nature.com/articles/s41591-024-03327-6</guid>
<content:encoded><![CDATA[
<div> <p>Nature Medicine, Published online: 25 October 2024; <a href="https://www.nature.com/articles/s41591-024-03327-6">doi:10.1038/s41591-024-03327-6</a></p>In participants with obesity and chronic kidney disease without diabetes, once-weekly administration of semaglutide 2.4 mg led to a reduction in albuminuria, body weight and systolic blood pressure compared with placebo, with no changes to creatinine or cystatin-C estimated glomerular filtration rate or measured glomerular filtration rate during the 24-week follow-up period. <div>
<p>Nature Medicine, Published online: 25 October 2024; <a href="https://www.nature.com/articles/s41591-024-03327-6">doi:10.1038/s41591-024-03327-6</a></p>In participants with obesity and chronic kidney disease without diabetes, once-weekly administration of semaglutide 2.4 mg led to a reduction in albuminuria, body weight and systolic blood pressure compared with placebo, with no changes to creatinine or cystatin-C estimated glomerular filtration rate or measured glomerular filtration rate during the 24-week follow-up period.
]]></content:encoded>

<pubDate>2024-10-25</pubDate>
</item>
<item>
<title>An explainable foundation model for drug repurposing</title>
<link>https://www.nature.com/articles/s41591-024-03333-8</link>
<guid>https://www.nature.com/articles/s41591-024-03333-8</guid>
<content:encoded><![CDATA[
<div> <p>Nature Medicine, Published online: 24 October 2024; <a href="https://www.nature.com/articles/s41591-024-03333-8">doi:10.1038/s41591-024-03333-8</a></p>A foundation model leverages large-scale medical knowledge to repurpose drugs for diseases that currently lack approved treatments, and provides explanations to support clinicians’ decisions. <div>
<p>Nature Medicine, Published online: 24 October 2024; <a href="https://www.nature.com/articles/s41591-024-03333-8">doi:10.1038/s41591-024-03333-8</a></p>A foundation model leverages large-scale medical knowledge to repurpose drugs for diseases that currently lack approved treatments, and provides explanations to support clinicians’ decisions.
]]></content:encoded>

<pubDate>2024-10-24</pubDate>
</item>

</channel>
</rss>